Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) Revenue (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Revenue for 7 consecutive years, with $427115.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 46.21% year-over-year to $427115.0, compared with a TTM value of $2.8 million through Oct 2025, up 187.51%, and an annual FY2025 reading of $2.7 million, up 366.47% over the prior year.
  • Revenue was $427115.0 for Q4 2025 at VitaNova Life Sciences, up from $103899.0 in the prior quarter.
  • Across five years, Revenue topped out at $2.0 million in Q2 2025 and bottomed at $3000.0 in Q2 2023.
  • Average Revenue over 5 years is $261454.2, with a median of $45000.0 recorded in 2021.
  • The sharpest move saw Revenue tumbled 93.33% in 2023, then surged 18053.13% in 2024.
  • Year by year, Revenue stood at $45000.0 in 2021, then crashed by 77.78% to $10000.0 in 2022, then tumbled by 70.0% to $3000.0 in 2023, then soared by 9637.27% to $292118.0 in 2024, then surged by 46.21% to $427115.0 in 2025.
  • Business Quant data shows Revenue for YJGJ at $427115.0 in Q4 2025, $103899.0 in Q3 2025, and $2.0 million in Q2 2025.